Skip to main content

Table 2 The Henan STEMI Registry data elements

From: Rationale and design of the Henan ST elevation myocardial infarction (STEMI) registry: a regional STEMI project in predominantly rural central China

CategoryExample elements
DemographicsDate of birth, sex, ethnicity, height, weight, marital status, occupation, education level, and medical insurance status
Medical history and risk factorsHypertension, hyperlipidemia, diabetes, smoking, prior stroke, family history of coronary heart disease, prior angina, prior MI, prior heart failure, prior revascularization, peripheral artery disease, chronic kidney disease, COPD, peptic ulcer and bleeding
Pre-hospital informationPatient (symptom onset date/time, symptoms, cardiac arrest)
First-contact hospital (hospital approaching method, first medical contact time, first ECG time, consent time, reperfusion strategies, DI-DO time, and transfer process)
In-hospital treatmentDepartment to arrive, first ECG date/time and findings, cardiac function classification, admission blood pressure, heart rate, infarct location, and Killip class
Reperfusion strategies, thrombolysis (time, thrombolytic agent, dose and outcome), primary and rescue PCI (time, coronary angiography results, culprit vessels, diameter and length of stent, TIMI flow before and after PCI, residual stenosis), and reasons why patients did not receive early reperfusion therapy
Treatment delay (hospital approaching method, first medical contact time, first ECG time, catheter lab ready time, consent time, FMC2B, FMC2N, and reasons of delay)
Laboratory resultsTroponin, CK-MB, CRP, BNP, NT-proBNP, lipids, hepatic and renal function, fasting glucose, HbA1c, blood routine test, ECG and UCG
MedicationsAntiplatelets, heparin, statin, β-blocker, ACEI or ARB, other medications used 1 week before MI onset, during hospitalization and at discharge
At dischargeDiagnosis, in-hospital duration, expense, reason for discharge, medication and MACCE (Death, reinfarction, in-stent thrombosis, heart failure, cardiogenic shock, cardiac arrest, mechanical complications, ischemic stroke, revascularization and bleeding)
Follow-upPresentation status (symptom, cardiac function classification, and smoking), medication, laboratory results and MACCE (death, reinfarction, in-stent thrombosis, congestive heart failure, rehospitalization, ischemic stroke, revascularization and bleeding)
  1. ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker, BNP Brain natriuretic peptide, CK-MB Creatine kinase MB isoenzyme, COPD Chronic obstructive pulmonary disease, CRP C-reactive protein, DI–DO Door in–door out, ECG Electrocardiograph, FMC2B First medical contact to balloon, FMC2N First medical contact to needle injection, HbA1c Glycosylated hemoglobin A1c, MACCE Adverse cardiovascular and cerebrovascular events, MI Myocardial infarction, NT-ProBNP N-terminal pro–brain natriuretic peptide, PCI Percutaneous coronary intervention, UCG Ultrasound cardiogram